Status:
RECRUITING
Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Human Papillomavirus
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood. These chronically infected pat...
Detailed Description
Screening for cervical cancer (CCU) is based on a well-codified, organized national screening program. However, unlike breast cancer or colorectal cancer, there is no personalized screening for patien...
Eligibility Criteria
Inclusion
- Chronic infected patients defined by: Patients with persistent HPV-HR cytological infection (high risk) (as early as 6 months post-treatment of a cervical or vaginal injury), or a recurrence of a high-grade squamous intraepithelial lesion (CIN2 or CIN3 or HSIL) or a recurrence of cancer in the cervix or vagina
- Patients who have given their written consent to participate in the study.
- Person affiliated or beneficiary of a social security scheme.
Exclusion
- Patient with an infection or a persistent lesion after treatment or not, linked only to low-risk HPV.
Key Trial Info
Start Date :
June 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04901351
Start Date
June 21 2022
End Date
December 1 2025
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Toulouse
Toulouse, France